Premier Alternatives

DIOSynVax

Hertford, United Kingdom · Founded 2017 · Privately Held (backing)

Operator of a vaccine antigen design company intended to accelerate vaccine development to maximize the protection against existing and future viruses. DIOSynVax is based in Hertford, United Kingdom and was founded in 2017. Its last reported valuation was $31.6 million in Dec 2025. It has raised $9.8 million.

Last reported valuation
$31.6M
Oct 2026
Priced at
—
Total raised
$9.8M
Last round
—

DIOSynVax key facts

as of Oct 2026
  • Operator of a vaccine antigen design company intended to accelerate vaccine development to maximize the protection against existing and future viruses.
  • DIOSynVax is valued at approximately $31.6M as of Oct 2026 (last reported valuation).
  • It has raised $9.8M; the latest was Later Stage VC ($8.1M) in Dec 2025.
  • Notable investors include Innovate UK, Gates Foundation, Parkwalk Advisors, Coalition for Epidemic Preparedness Innovations, Flu lab — 7 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$31.6M

DIOSynVax's last reported valuation, Dec 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of DIOSynVax with a free Private Market View account
  • ·Watch DIOSynVax: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

DIOSynVax funding rounds

No rounds on record

No funding rounds for DIOSynVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

DIOSynVax valuation

DIOSynVax's last reported valuation was $31.6 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.

DIOSynVax investors

7 investors are on record for DIOSynVax, including Innovate UK, Gates Foundation, Parkwalk Advisors and Coalition for Epidemic Preparedness Innovations.

About DIOSynVax

Operator of a vaccine antigen design company intended to accelerate vaccine development to maximize the protection against existing and future viruses. The company offers services that leverage technology to digitally design, immune-optimized selected and synthesized vaccines to achieve dramatic improvements in protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral hemorrhagic fevers, enabling doctors to treat and help patients recover quickly from diseases.

Sector
Healthcare
HQ
Hertford, United Kingdom
Founded
2017
Employees
17
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.